Matthew Swanic, MD
Ophthalmology · Las Vegas, NVNPI 1659496909
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,114 of the $6,114 with a category attached, or 83.6%. 27 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 25.9% of the total. Reporting peaked in 2023 at $1,870 and has fallen 76.2% since, to $445 in 2025.
Across 160 payments — averaging $38.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$2K
- Sun Pharmaceutical Industries Inc.$516
- Johnson & Johnson Surgical Vision, Inc.$471
- Kala Pharmaceuticals, Inc.$452
- Alcon$430
- AbbVie$376
- plus $2K from 21 others
Across 38 payments — averaging $11,246 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$151K
- Padagis US LLC$125K
- Novartis$108K
- Kala Pharmaceuticals, Inc.$31K
- Perrigo Company PLC$12K
- Alcon Research LLC$874
What the payments were for
- Travel & lodging$92015%
- Food & beverage$5,11484%
- Education$50%
- Gifts$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 8 | $1,582 |
| Sun Pharmaceutical Industries Inc. | 21 | $516 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $471 |
| Kala Pharmaceuticals, Inc. | 14 | $452 |
| Alcon | 13 | $430 |
| AbbVie(2 entities) | 20 | $376 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $347 |
| Carl Zeiss Meditec, Inc. | 7 | $320 |
| Shire North American Group Inc | 7 | $189 |
| Bausch & Lomb Americas Inc. | 9 | $163 |
| Mallinckrodt Hospital Products Inc. | 6 | $144 |
| Novartis | 3 | $141 |
| Glaukos Corporation | 1 | $134 |
| Amgen | 1 | $122 |
| Mallinckrodt Enterprises LLC | 1 | $118 |
| ANI Pharmaceuticals, Inc. | 5 | $113 |
| Eyepoint US, Inc. | 1 | $82 |
| Tarsus Pharmaceuticals, Inc. | 3 | $68 |
| Rxsight Inc | 3 | $66 |
| Oyster Point Pharma, Inc. | 3 | $60 |
| Optos, Inc. | 2 | $45 |
| Alcon Research LLC | 2 | $44 |
| Dompe US, Inc. | 2 | $42 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Sight Sciences, Inc. | 1 | $14 |
| Merz North America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$1,176
- ARTEVO 800$1,056
- CIRRUS HD-OCT$1,056
- IOLMaster 700$1,056
- VERACITY SURGICAL$1,056
- Clareon$189
- LOTEMAX SM$150
- iStent Trabecular Micro-Bypass Stent System$134
- iStent inject Trabecular Micro-Bypass Stent System$134
- CEQUA$125
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$124
- XIIDRA$122
- TEPEZZA$122
- INVELTYS$120
- ACTHAR$118
- Tecnis Simplicity$114
- EYSUVIS$111
How this compares
$6,114 in reported general payments places this provider in the 80th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 41 | $23,550 |
| ProlensaBromfenac Sodium | 44 | $14,707 |
| Prednisolone Acetate | 326 | $10,951 |
| MoxifloxacinMoxifloxacin Hcl | 200 | $4,635 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $4,285 |
| Fluorometholone | 60 | $4,248 |
| Latanoprost | 304 | $2,597 |
| Difluprednate | 20 | $2,510 |
| Timolol Maleate | 127 | $1,164 |
| ErythromycinErythromycin Base | 18 | $415 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $359 |
| Doxycycline Hyclate | 21 | $325 |
| Brimonidine Tartrate | 12 | $96 |
| Prednisone | 16 | $0 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $376 | $23,55041 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $347 | $14,70744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.